The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
OPDIVO Bristol-Myers Squibb Australia Pty Ltd
Product name
OPDIVO
Accepted date
Oct-2024
Active ingredients
nivolumab
Proposed indication
For the treatment of advanced hepatocellular carcinoma or hepatocellular carcinoma that cannot be removed surgically.
Application type
C (new indication)
Publication date
Oct-2024